<PAGE>
Rule 424(b)(3)
333-10839
SUPPLEMENT NO. 6 DATED MARCH 17, 1997
TO PROSPECTUS DATED SEPTEMBER 3, 1996
RELATING TO $125,000,000 PRINCIPAL AMOUNT 5 5/8% CONVERTIBLE
SUBORDINATED NOTES DUE 2006 AND
3,654,971 SHARES OF
RENAL TREATMENT CENTERS, INC.
COMMON STOCK, $.01 PAR VALUE
All capitalized terms used but not defined herein shall have the meanings
prescribed in the Prospectus dated September 3, 1996, as supplemented by
Supplement No. 1 dated December 2, 1996, Supplement No. 2 dated December 9,
1996, Supplement No. 3 dated January 6, 1997, Supplement No. 4 dated January 13,
1997 and Supplement No. 5 dated February 18, 1997, forming a part of Form S-3
Registration Statement No. 333-10839.
The purpose of this supplement is to provide additional information
regarding the Selling Securityholders. The Selling Securityholder in the table
below is identified by this supplement. The Notes beneficially owned by the
Selling Securityholder were previously listed in the Prospectus under the name
of the nominee or Depository Trust Company participant holding the Notes for the
benefit of the previous holder from whom the Selling Securityholder purchased
the Notes. The table has been prepared based upon information furnished to the
Company by or on behalf of the Selling Securityholder identified therein.
<TABLE>
<CAPTION>
Principal Amount Number of
of Notes Benefi- Conversion Percentage
cially Owned Percentage Shares of Common
That May of Notes That May Stock
Name Be Sold Outstanding Be Sold (1) Outstanding (2)
- ---- ------- ----------- ----------- --------------
<S> <C> <C> <C> <C>
Donaldson Lufkin & Jenrette $600,000 * 17,543 *
Securities Corp.
- --------------------------
</TABLE>
* Less than 1%.
(1) Assumes conversion of the full amount of Notes held by such holder at the
current conversion rate of $34.20 in principal amount of Notes per share of
Common Stock. Under the terms of the Indenture, fractional shares will not be
issued upon conversion of the Notes; cash will be paid in lieu of fractional
shares, if any.
(2) Computed in accordance with Rule 13d-3(d)(i) promulgated under the Exchange
Act based upon the 24,393,056 shares of Common Stock outstanding as of January
31, 1997, treating as outstanding the number of Conversion Shares shown as being
issuable upon the assumed conversion by the named holder of the full amount of
such holder's Notes but not assuming the conversion of the Notes of any other
holders.
Other than its ownership of the Company's securities, the foregoing Selling
Securityholder has not had any material relationship with the Company within the
past three years.
